financetom
Business
financetom
/
Business
/
TikTok creators file suit to block US divestment or ban law
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TikTok creators file suit to block US divestment or ban law
May 14, 2024 12:22 PM

WASHINGTON, May 14 (Reuters) - A group of TikTok

creators said Tuesday they filed suit in U.S. federal court

seeking to block a law signed by President Joe Biden that would

force the divestiture of the short video app used by 170 million

Americans or ban it.

"Although they come from different places, professions,

walks of life, and political persuasions, they are united in

their view that TikTok provides them a unique and irreplaceable

means to express themselves and form community," said the

lawsuit.

Davis Wright Tremaine LLP, a law firm representing the

creators, provided a copy of the lawsuit to Reuters it said had

been filed in the U.S. Court of Appeals for the District of

Columbia Circuit.

The suit, which seeks injunctive relief, says the law

threatens free speech and "promises to shutter a discrete medium

of communication that has become part of American life."

Last week, TikTok and its Chinese parent company ByteDance

filed a similar lawsuit, arguing that the law violates the U.S.

Constitution on a number of grounds including running afoul of

First Amendment free speech protections.

TikTok creators filed a similar suit in 2020 to block a

prior attempt to block the app, and also sued last year in

Montana asking a court to block a state ban.

The law, signed by Biden on April 24, gives ByteDance until

Jan. 19 to sell TikTok or face a ban. The White House has said

it wants to see Chinese-based ownership ended on national

security grounds but not a ban on TikTok.

The law prohibits app stores like Apple ( AAPL ), and

Alphabet's Google, from offering TikTok and bars

internet hosting services from supporting TikTok unless

ByteDance divests TikTok by Jan. 19.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved